

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7919653

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PATRICK SHANNON	01/24/2017
RECEIVING PARTY DATA	
Name:	CANCER PREVENTION PHARMACEUTICALS, INC.
Street Address:	1760 E. RIVER ROAD
City:	TUCSON
State/Country:	ARIZONA
Postal Code:	85718
PROPERTY NUMBERS Total: 2	
Property Type	Number
PCT Number:	US1659689
Patent Number:	11529326
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5123342900
Email:	kdainty@phiplaw.com
Correspondent Name:	PARKER HIGHLANDER PLLC
Address Line 1:	1120 S. CAPITAL OF TEXAS HIGHWAY
Address Line 4:	AUSTIN, TEXAS 78746
ATTORNEY DOCKET NUMBER:	CAPP.P0017WO & C1
NAME OF SUBMITTER:	KAREN DAINTY
SIGNATURE:	/Karen Dainty/
DATE SIGNED:	04/25/2023
Total Attachments: 2	
source=CAPP.P0017US - PCT Assignment_Shannon to CPP#page1.tif	
source=CAPP.P0017US - PCT Assignment_Shannon to CPP#page2.tif	

ASSIGNMENT

FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, the undersigned, does hereby:

SELL, ASSIGN AND TRANSFER to CANCER PREVENTION PHARMACEUTICALS, INC. (the "Assignee"), having a place of business at 1760 E. River Road, Suite 250, Tucson, AZ 85718, the entirety of their right, title and interest for the United States and all foreign countries in and to any and all improvements which are disclosed in the following:

European Patent Application, Serial No. 16306429.8, filed October 28, 2016, entitled "EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION";

European Patent Application, Serial No. 16306430.6, filed October 28, 2016, entitled "EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION"; and

International Patent Application, Serial No. PCT/US2016/059689, filed October 31, 2016, entitled "EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION" which claims priority to United States Patent Application, Serial No. 62/248,810, filed October 30, 2015, United States Patent Application, Serial No. 62/358,698, filed July 6, 2016, European Patent Application, Serial No. 16306429.8, filed October 28, 2016, and European Patent Application, Serial No. 16306430.6, filed October 28, 2016.

These applications and all conversion, divisional, continuing, substitute, renewal, reissue and all other applications for patent which have been or shall be filed in the United States and all foreign countries on any of such improvements; all original and reissued patents which have been or shall be issued in the United States and all foreign countries on such improvements; and specifically including the right to file foreign applications under the provisions of any convention or treaty and claim priority based on such applications;

AUTHORIZE AND REQUEST the issuing authority to issue any and all United States and foreign patents granted on such improvements to the Assignee;


WARRANT AND COVENANT that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or will be made to others by the undersigned, and that the full right to convey the same as herein expressed is possessed by the undersigned;

COVENANT, when requested and at the expense of the Assignee, to carry out in good faith the intent and purpose of this assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on any and all such

improvements; execute all rightful oaths, declarations, assignments, powers of attorney and other papers; communicate to the Assignee all facts known to the undersigned relating to such improvements and the history thereof; and generally do everything possible which the Assignee shall consider desirable for vesting title to such improvements in the Assignee, and for securing, maintaining and enforcing proper patent protection for such improvements;


TO BE BINDING on the heirs, assigns, representatives and successors of the undersigned and extend to the successors, assigns and nominees of the Assignee.


The assignment of said invention is effective as of the earlier of (1) the date of execution shown below or (2) the filing date of the first filed of said patent applications.

Signature:  Date: 24 Jan 2017
Name: Patrick SHANNON

STATE OF Florida
COUNTY OF Escambia

BEFORE ME, the undersigned authority, on this 24 day of January, 2017 personally appeared Patrick SHANNON known to me to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he/she executed the same of his/her own free will for the purposes and consideration therein expressed.


Notary or Consular Officer



PARKER HIGHLANDER PLLC
1120 S. Capital of Texas Highway
Building One, Suite 200
Austin, TX 78746